Exonhit and BGI Announce Successful Completion of a Promising Next-Generation Sequencing Project
Combining complementary platforms facilitates rapid and comprehensive discovery and development of biologically relevant markers
Exonhit and BGI announced the successful completion of a project dedicated to expanding Exonhit’s Genome-Wide SpliceArrayTM to an additional strategic preclinical animal model species.
To answer the need for a comprehensive understanding of gene deregulation and the expanding interest in developing biomarkers and molecular diagnostic tests for complex diseases, Exonhit and BGI decided to leverage their technology and know-how by combining the complementary features of massive parallel sequencing and Exonhit’s proprietary SpliceArray™ platform.
“Combining BGI’s next-generation sequencing ability with the profiling efficiency of Exonhit unique SpliceArray™ platform to discover new transcript content will enable a better understanding of the biology contributing to the onset and progression of disease. This new powerful combination will facilitate the rapid discovery, development and commercialization of the most relevant therapeutics, biomarkers and molecular diagnostics. We look forward to working with BGI as a preferred partner on future discovery projects,” commented Matthew Pando, Ph.D., Executive Vice President, Therapeutics at Exonhit.
“There is a high need for biomarker discovery as Pharma and Biotech players search for prognostic and predictive biomarkers in animal models, for designing clinical trials and developing companion diagnostics,” said Zifei Yang, Director of Pharma Business Development at BGI. “BGI Europe is pleased to partner with Exonhit to leverage BGI’s next-generation sequencing technology with Exonhit’s SpliceArray™ platform.”
Most read news
Organizations
Other news from the department science
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.